Fusion protein · Antagonist of TGF-beta family proteins · developed by TAKEDA PHARMACEUTICAL CO
Elritercept is a recombinant fusion protein composed of the ligand-binding domain of activin receptor type IIA linked to the Fc domain of human antibody. It acts as a ligand trap, binding TGF-beta family proteins and blocking their signaling to promote hematopoiesis and increase red blood cell and platelet production. It is studied in myelodysplastic syndrome and anemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07422480 | Phase 3 | Myelodysplastic Syndrome | Recruiting | TAK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AnemiaMyelodysplastic Syndrome
Updated Oct 3, 2026. Something wrong or missing? Report it on the TAK page.
See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TAK catalysts and pipeline →